Immunome, Inc. (IMNM) Ownership
IMNM ownership summary
as of October 18, 2026- Institutions
- 102.8% of shares outstanding
- Insiders
- 6.32% of shares outstanding
- Shares outstanding
- 118.0M
- Float
- 108.7M shares available to trade
- Short interest
- 17.25% 16.8M shares short
- Days to cover
- 13.16 short interest up 3.2% vs prior month
- Institutions 102.80%
- Insiders 6.32%
IMNM top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management,Inc. | 17.35% | 19.7M | $324.1M | +3.3M (+20.2%) | June 30, 2026 |
| 2 | FMR Inc | 14.98% | 17.0M | $279.8M | +17,599 (+0.1%) | June 30, 2026 |
| 3 | BlackRock Inc | 7.76% | 8.8M | $145.0M | +636,818 (+7.8%) | June 30, 2026 |
| 4 | State Street Corp | 4.85% | 5.5M | $90.5M | +94,724 (+1.8%) | June 30, 2026 |
| 5 | Wellington Management Company LLP | 4.59% | 5.2M | $85.8M | +478,239 (+10.1%) | June 30, 2026 |
| 6 | Redmile Group, LLC | 4.33% | 4.9M | $80.9M | −647,295 (−11.6%) | June 30, 2026 |
| 7 | PRIMECAP Management Company | 4.04% | 4.6M | $75.5M | −206,800 (−4.3%) | June 30, 2026 |
| 8 | Vanguard Capital Management, LLC | 4.01% | 4.6M | $75.0M | +121,592 (+2.7%) | June 30, 2026 |
| 9 | Driehaus Capital Management LLC | 3.83% | 4.3M | $71.6M | +246,238 (+6.0%) | June 30, 2026 |
| 10 | Enavate Sciences GP, LLC | 3.19% | 3.6M | $59.5M | — | June 30, 2026 |
| 11 | Geode Capital Management, LLC | 2.43% | 2.8M | $45.4M | +194,225 (+7.6%) | June 30, 2026 |
| 12 | Morgan Stanley - Brokerage Accounts | 2.12% | 2.4M | $39.7M | −433,647 (−15.3%) | June 30, 2026 |
| 13 | SILVERARC CAPITAL MANAGEMENT, LLC | 1.78% | 2.0M | $33.2M | +166,731 (+9.0%) | June 30, 2026 |
| 14 | JPMorgan Chase & Co | 1.63% | 1.8M | $30.4M | −929,288 (−33.5%) | June 30, 2026 |
| 15 | T. Rowe Price Associates, Inc. | 1.56% | 1.8M | $29.2M | −1.1M (−38.0%) | June 30, 2026 |
| 16 | Sofinnova Ventures | 1.52% | 1.7M | $28.3M | +18,412 (+1.1%) | June 30, 2026 |
| 17 | Readystate Asset Management LP | 1.42% | 1.6M | $26.4M | +303,958 (+23.3%) | June 30, 2026 |
| 18 | The Goldman Sachs Group Inc | 1.33% | 1.5M | $24.9M | +411,013 (+37.3%) | June 30, 2026 |
| 19 | Vanguard Portfolio Management, LLC | 1.19% | 1.3M | $22.2M | +342,004 (+34.0%) | June 30, 2026 |
| 20 | Principal Financial Group Inc | 1.19% | 1.3M | $22.2M | −29,509 (−2.1%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 6.3M shares and 6 cut 3.3M.
IMNM top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | T. Rowe Price Small-Cap Stock | 6.49% | 7.4M | $121.2M | +32,800 (+0.4%) | August 31, 2026 |
| 2 | Fidelity Growth Company Fund | 4.32% | 4.9M | $80.8M | +15,128 (+0.3%) | August 31, 2026 |
| 3 | T. Rowe Price Instl Small-Cap Stock | 3.54% | 4.0M | $66.1M | +36,892 (+0.9%) | August 31, 2026 |
| 4 | PRIMECAP Odyssey Aggressive Growth | 3.26% | 3.7M | $60.8M | −174,600 (−4.5%) | June 30, 2026 |
| 5 | Vanguard MStar Total Stk Mkt Idx Invest | 2.85% | 3.2M | $53.3M | −6,234 (−0.2%) | August 31, 2026 |
| 6 | Vanguard Health Care Inv | 2.53% | 2.9M | $47.2M | +89,621 (+3.2%) | June 30, 2026 |
| 7 | iShares Russell 2000 ETF | 2.41% | 2.7M | $45.0M | −31,488 (−1.1%) | September 30, 2026 |
| 8 | Fidelity Select Biotechnology | 1.88% | 2.1M | $35.1M | — | August 31, 2026 |
| 9 | State Street® SPDR® S&P® Biotech ETF | 1.73% | 2.0M | $32.3M | −37,550 (−1.9%) | September 30, 2026 |
| 10 | T. Rowe Price Small-Cap Value | 1.47% | 1.7M | $27.5M | −15,287 (−0.9%) | August 31, 2026 |
| 11 | Fidelity Growth Company K6 | 1.25% | 1.4M | $23.3M | +4,400 (+0.3%) | August 31, 2026 |
| 12 | Fidelity Series Growth Company | 1.10% | 1.2M | $20.5M | +4,023 (+0.3%) | August 31, 2026 |
| 13 | Fidelity Small Cap Index | 1.02% | 1.2M | $19.0M | +9,970 (+0.9%) | July 31, 2026 |
| 14 | iShares Russell 2000 Growth ETF | 0.87% | 987K | $16.3M | −1,249 (−0.1%) | September 30, 2026 |
| 15 | JPMorgan Small Cap Growth A | 0.74% | 843K | $13.9M | −24,866 (−2.9%) | August 31, 2026 |
| 16 | T. Rowe Price Health Sciences | 0.70% | 797K | $13.1M | −296,300 (−27.1%) | August 31, 2026 |
| 17 | Heptagon Driehaus US Micro Cap Eq C$ Acc | 0.67% | 765K | $12.6M | — | August 31, 2026 |
| 18 | Vanguard Russell 2000 ETF | 0.53% | 606K | $10.0M | +14,336 (+2.4%) | August 31, 2026 |
| 19 | Schwab US Small-Cap ETF™ | 0.53% | 598K | $9.8M | +396 (+0.1%) | September 30, 2026 |
| 20 | BNP Paribas US Small Cap ClassicC | 0.51% | 575K | $9.5M | −1,102 (−0.2%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
IMNM insider transactions
latest 11| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-02 | Jack Higgins | Sell | $21.64 | 9,438 | $204,238 |
| 2026-04-02 | Max Rosett | Sell | $21.92 | 65,000 | $1.4M |
| 2026-03-23 | Philip Wagenheim | Sell | $20.65 | 28,200 | $582,330 |
| 2026-03-20 | Philip Wagenheim | Sell | $20.47 | 36,800 | $753,296 |
| 2026-03-11 | Jean Jacques Bienaime | Buy | $21.55 | 1,000 | $21,550 |
| 2025-12-30 | Clay B Siegall | Buy | $21.15 | 4,729 | $100,018 |
| 2025-12-22 | Isaac Barchas | Sell | $21.74 | 383,200 | $8.3M |
| 2025-12-19 | Clay B Siegall | Buy | $20.48 | 7,278 | $149,053 |
| 2025-12-19 | Philip Tsai | Buy | $20.49 | 10,000 | $204,900 |
| 2025-12-18 | Clay B Siegall | Buy | $21.50 | 46,511 | $999,986 |
| 2025-06-03 | Jean Jacques Bienaime | Buy | $9.38 | 5,000 | $46,900 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
IMNM shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns IMNM
Institutional investors own 102.8% of Immunome's shares and insiders 6.32%. The largest holder is T. Rowe Price Investment Management,Inc. with 17.35% of the shares (19.7M), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 6 reduced their stake in the latest filings. Short interest is 17.25% of the float, or 13.16 days of average trading volume. The share count rose 8,635.1% since 2018.
Related: IMNM analyst forecast, IMNM key metrics. See the IMNM stock overview for the latest quote and news.
IMNM ownership FAQ
Who owns the most Immunome stock?
The largest shareholders of Immunome are T. Rowe Price Investment Management,Inc. (17.35%), FMR Inc (14.98%), BlackRock Inc (7.76%), State Street Corp (4.85%), Wellington Management Company LLP (4.59%).
What percentage of Immunome is owned by institutions?
Institutions hold 102.8% of Immunome's shares outstanding; insiders hold 6.32%.
Which funds own Immunome?
The largest fund holders of Immunome are T. Rowe Price Small-Cap Stock (6.49%), Fidelity Growth Company Fund (4.32%), T. Rowe Price Instl Small-Cap Stock (3.54%), PRIMECAP Odyssey Aggressive Growth (3.26%), Vanguard MStar Total Stk Mkt Idx Invest (2.85%).
What is Immunome's short interest?
16.8M shares of Immunome were sold short, 17.25% of the float; at the average daily volume it would take 13.16 days to cover.
Are insiders buying or selling Immunome?
Of the latest 11 reported insider transactions in Immunome (since June 3, 2025), 6 were purchases and 5 were sales.
How many shares of Immunome are outstanding?
Immunome has 118.0M shares outstanding, of which 108.7M are in the public float.